Advocacy intelligence hub — real-time data for patient organizations
Zemplar: FDA approved
Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Zemplar
Abbvie, inc.
Zemplar
(paricalcitol)Orphan drugAbbvie, inc.
Vitamin D2 Analog [EPC]
12.1 Mechanism of Action Paricalcitol is a synthetic, biologically active vitamin D 2 analog of calcitriol. Preclinical and in vitro studies have demo...